London biotech secures £90 million backing
![London biotech secures £90 million backing](https://static.standard.co.uk/2024/07/09/9/51/Myricx-Bio-scientific-founders-and-CEO-in-Lab-c--Imperial-Jason-Alden.jpg?width=1200&auto=webp)
Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers
Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers